[ad_1]
LONDON–(BUSINESS WIRE)–Technavio has announced their latest pipeline analysis report on the Behcet’s
syndrome market. The report includes a detailed analysis of the
pipeline molecules under investigation within the defined data
collection period to treat Behcet’s syndrome.
This report by Technavio presents a detailed analysis of the market,
including regulatory framework, drug development strategies, recruitment
strategies, and key companies that are expected to play an essential
role in the growth of the market in the future.
This report is available at a USD 1,000 discount for a limited time
only: View
market snapshot before purchasing
Behcet’s syndrome: Market overview
Behcet’s syndrome or Behcet’s disease is a rare type of autoimmune
disorder that results in inflammation of blood vessels throughout the
body. It affects multiple body parts. The complications caused due to
Behcet’s syndrome depends on the site of the body parts and symptoms.
For instance, untreated uveitis, the inflammation of the middle layer of
the eye between the retina and sclera, can result in decreasing vision
or even blindness.
According to a senior market research analyst at Technavio, “Behcet’s
syndrome tends to develop more in young adults who are in their 20s and
30s of all genders and races, however, it can occur in all ages. It is
most prevalent in Turkey, while in Middle Eastern countries, males are
more affected than females. However, in the US, Japan, South Korea and
other countries it occurs more in females. The prevalence of the
syndrome is increasing throughout the world due to better disease
recognition and reporting of cases.”
Behcet’s syndrome: Segmentation analysis
This pipeline analysis report segments the Behcet’s syndrome market
based on therapies employed (monotherapy), RoA (oral, parenteral and
subcutaneous), therapeutic modality (fusion protein, monoclonal
antibody, small molecule, and recombinant protein), targets (interleukin
1 beta, phosphodiesterase (PDE) 4, regulatory t-lymphocyte, t-cell, and
tumor necrosis factor alpha), MoA (interleukin 1 beta inhibitors, PDE 4
inhibitors, regulatory t-lymphocyte stimulants, t-cell activation
inhibitors, and tumor necrosis factor alpha inhibitors), geographical
segmentation (France, Korea, Turkey and US) and recruitment status
(recruiting, and active, not recruiting). It provides an in-depth
analysis of the prominent factors influencing the market, including
drivers, opportunities, trends, and industry-specific challenges.
In the current pipeline, more than 33% of the molecules that are being
investigated based on therapeutic modality, for the treatment of
Behcet’s syndrome are fusion protein.
Looking for more information on this market? Request
a free sample report
Technavio’s sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Regulatory Framework
Drug Development Landscape
- Drugs under development
- Indications coverage
Drug Development Strategies
- Therapies employed
- RoA
- Therapeutic modality
- Geographical coverage
Recruitment Strategies
- Recruitment status
- Gender
- Age
Key Companies
- Type of players
- Company overview
Discontinued or Dormant Molecules
About Technavio
Technavio
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio’s comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team
at media@technavio.com.
[ad_2]
Source link
